Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7707 results

  1. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

    This guideline has been updated and replaced by NICE guideline NG245.

    NICE guideline
    Last updated
    22 March 2021

  2. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    23 August 2000

  3. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    26 March 2008

  4. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    28 November 2007

  5. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Diagnostics guidance
    Published
    2 April 2014

  6. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development [GID-TA10843] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    Discontinued [GID-TA11005]

    Technology appraisal guidance
    Discontinued

  8. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued [GID-TA11399]

    Technology appraisal guidance
    Discontinued

  9. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued [GID-TA11421]

    Technology appraisal guidance
    Discontinued

  10. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued [GID-TA10316]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued [GID-TA11024]

    Technology appraisal guidance
    Discontinued

  12. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1018.

    Technology appraisal guidance
    Published
    16 December 2021

  13. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    29 July 2014

  14. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

    Technology appraisal guidance
    Discontinued

  15. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued